arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

IMPACT BIOMEDICAL INC.

IBO

$6.62 ▲ +6.08 (+1123.66%) at close

17 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

IMPACT BIOMEDICAL INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $713.8M

Dividend Yield —

Revenue Growth -57.1%

Op. Margin —

ROIC -5.2% ↗

FCF / Share $0.00 ↗

Trailing P/E —

Price / Book 66.3x

FCF Yield 0.1%

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

17-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.00K

↓ -57.1% —

Net Income Profit after all expenses

$-699.00K

↑ +95.1% —

FCF / Share Free cash flow per share

$0.00

↑ +201.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Revenue Growth YoY (%)	-57.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-814%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	99.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	81.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-1211.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-10.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-8333.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	—	-900.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	25.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	95.1% Excellent Excellent Year-over-year change in net income	-80.5% Weak Weak Year-over-year change in net income	N/M	N/M	-1522.9% Weak ↓ Weak Declining Year-over-year change in net income	-27.0% Weak ↑ Weak Improving Year-over-year change in net income	-2178.0% Weak ↓ Weak Declining Year-over-year change in net income	N/M	21.1% Good ↓ Good Declining Year-over-year change in net income	-17.6% Weak ↓ Weak Declining Year-over-year change in net income	64.6% Excellent ↑ Excellent Improving Year-over-year change in net income	47.4% Excellent Excellent Year-over-year change in net income	-40.3% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	—	92.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	20.6% Good Good Year-over-year change in free cash flow	—	—	—	-395.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	-48.1% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Effective Tax Rate (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	35.8% Weak Weak Actual taxes paid relative to pre-tax income Optimal: 15-25%	-128.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	-0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.20x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.02x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.42x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.54x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.04x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.36x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.19x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.11x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.36x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Return on Invested Capital (%)	-5.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-15.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.3% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	8.8% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	-20.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-486.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-2.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-2.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-2.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-2.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-2.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-4.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-5.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-129.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-2.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-1.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-2.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-2.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-2.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-2.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-6.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-143%)	-19.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-233%)	41.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+177%)	12.4% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-17%)	138.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+825%)	-33.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-320%)	—	13.5% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-10%)	-3.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-125%)	-4.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	-4.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-4.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-130%)	-4.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	—	-11.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-176%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Interest Coverage (x)	—	—	—	-3.62x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-4.43x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3.73x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-97.15x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-3.70x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2.40x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3.35x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.11x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-10.57x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-8.69x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-7.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-10.42x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-9.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	-5.40x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	—	$-20.00K	$-3.00K	$-12.00K	$-624.00K	$-1.32M	$-2.00M	$-2.67M	$-2.00K	$-2.00K	$-1.00K	$-201.00K	$-3.00K	—	$-2.00K	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Revenue per Share (USD)	$0.00	$0.00	—	$0.00	$0.00	—	—	—	—	—	—	—	—	—	—	$0.00	$0.00
Basic EPS, GAAP (USD)	$-0.01	$-0.02	$1.03	$-0.12	$-1.18	$-0.11	$-2.53	$0.37	$-0.09	$-0.10	$-0.03	$-0.02	$0.00	$-0.01	$-0.04	$-0.03	$0.00
Free Cash Flow per Share (USD)	$0.00	$-0.00	—	$-0.05	—	$-0.06	—	—	—	$-0.07	—	—	—	$-0.01	—	$-0.01	—
Book Value per Share (USD)	$0.10	$0.11	$0.12	$-0.97	$-0.85	$0.32	$0.37	$2.72	$2.34	$2.43	$2.52	$0.38	$0.01	—	$0.42	—	—
Tangible Book Value per Share (USD)	$0.10	$0.11	$0.12	$-0.97	$-0.85	$0.32	$0.37	$0.54	$-0.17	$-0.08	$-2.12	$0.02	$0.00	—	$0.06	—	—
Basic Weighted Avg Shares (shares)	107.82M	107.79M	—	12.19M	12.19M	12.06M	—	11.50M	10.00M	10.00M	—	70.50M	3.88B	70.50M	—	70.50M	3.88B

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Working Capital (USD)	$-1.73M	$-1.31M	$-751.00K	$-22.88M	$-21.69M	$-7.79M	$-7.34M	$2.04M	$-14.19M	$-13.52M	$-12.80M	$-11.77M	$-11.71M	—	$-10.47M	—	—
Total Equity (USD)	$10.77M	$11.46M	$12.61M	$-11.81M	$-10.34M	$3.84M	$4.26M	$31.35M	$23.37M	$24.26M	$25.22M	$26.52M	$27.62M	—	$29.56M	—	—

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 May 10, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Sales/Revenue/Turnover (USD)	$3.00K	$7.00K	$7.00K	$18.00K	$7.00K	—	—	—	—	—	—	—	—	—	$0.00	$0.00	$50.00K
Depreciation Expense (USD)	$284.00K	$285.00K	$286.00K	$288.00K	$2.00K	$283.00K	$279.00K	—	—	$280.00K	$280.00K	—	—	$280.00K	$278.00K	$279.00K	—
Net Income, GAAP (USD)	$-699.00K	$-2.29M	$5.25M	$-1.47M	$-14.35M	$-1.27M	$-27.11M	$4.24M	$-884.00K	$-998.00K	$-1.19M	$-1.18M	$-1.12M	$-849.00K	$-3.37M	$-2.24M	$-799.00K
Operating Cash Flow (USD)	$470.00K	$-464.00K	$99.00K	$-613.00K	—	$-682.00K	$-986.00K	—	—	$-712.00K	$-433.00K	—	—	$-1.01M	$-363.00K	$-802.00K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 17 quarters

IMPACT BIOMEDICAL INC.

Analytical Summary

17-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IBO with peers